The results were announced from a phase 3 study in which the effectiveness and security of molnupiravir for prophylaxis after exposure to prevent covid-19 was evaluated.
The multicenter, randomized, double-blind, placebo-controlled moving study (clinicalaltrials.gov identifier: nct04939428) wrote over 1500 participants who are 18 years old and older who tested in the same household with someone who tested positively for Sars-Cov, and at least 1 signs of symptoms, and the symptom Out of 1, and the symptom of 1.10 days, and not 5 days, and at least 1-mind at the latest symptom of 5 days, had at least 5 days. People who received the first dose of a Covid 19 vaccine more than 7 days before the registration had previously had covid-19 in the past 6 months or showed signs or symptoms of covid-19 from the study.
The participants randomly received Molnupiravir 800 mg oral or placebo every 12 hours for 5 days. The results showed that during treatment with Molnupiravir, the probability of a covid-19 development of 23.6% decreased to the 14th day compared to placebo. In the study, the study missed the primary end point, which had not achieved statistically significant reduction in the risk of Covid-199 after another person with covid with covid-19.
Molnupiravir’s security profile matched what was observed in previous studies and, according to the authorization data in COVID-19 treatment. Molnupiravir is currently being marketed under the brand name Lage Vrio and approved for the treatment of certain adults for the treatment of certain adults, in which slight to moderate covid-19 was diagnosed.
“The results of this study on prevention after exposure are scientifically interesting because we continue to learn more about Covid-19,” said Dr. Dean Y. Li, President of Merck Research Laboratories. “This was not a treatment study, and these results have no influence on the effectiveness and safety data observed in our phase 3 study for the treatment of light to moderate covid-19.”
The final analysis from the moving-out study showed that treatment with Molnupiravir reduced the risk of hospitalization or death by 30% in endangered patients with mild to moderate covid-19.
reference
Merck provides update of the phase 3 Move-AHEAD study to evaluate LAGEVRIIO (Molnupiravir) for prophylaxis after exposure to prevent COVID-19. Press release. Merck. Access on February 21, 2023. https://www.businesswire.com/news/20230221005404/en/merck-provides-update-on-phase-ahead-tr Ial-Evaluating-Latinvrio%E2%84%A2-Molnupiravir-for-Post-Exposure-Prophylaxis-For-Prevention-of-Covid-19.
This article originally appeared on MPR